1. Myeloid Targeted Human MLL-ENL and MLL-AF9 Induces cdk9 and bcl2 Expression in Zebrafish Embryos.
- Author
-
Belt, Alex J., Grant, Steven, Tombes, Robert M., and Rothschild, Sarah C.
- Subjects
- *
BRACHYDANIO , *DRUG discovery , *ACUTE myeloid leukemia , *EMBRYOS , *HEMATOLOGIC malignancies , *CHROMOSOMAL rearrangement - Abstract
Acute myeloid leukemia (AML) accounts for greater than twenty thousand new cases of leukemia annually in the United States. The average five-year survival rate is approximately 30%, pointing to the need for developing novel model systems for drug discovery. In particular, patients with chromosomal rearrangements in the mixed lineage leukemia (MLL) gene have higher relapse rates with poor outcomes. In this study we investigated the expression of human MLL-ENL and MLL-AF9 in the myeloid lineage of zebrafish embryos. We observed an expansion of MLL positive cells and determined these cells colocalized with the myeloid markers spi1b, mpx, and mpeg. In addition, expression of MLL-ENL and MLL-AF9 induced the expression of endogenous bcl2 and cdk9, genes that are often dysregulated in MLL-r-AML. Co-treatment of lyz: MLL-ENL or lyz:MLL-AF9 expressing embryos with the BCL2 inhibitor, Venetoclax, and the CDK9 inhibitor, Flavopiridol, significantly reduced the number of MLL positive cells compared to embryos treated with vehicle or either drug alone. In addition, cotreatment with Venetoclax and Flavopiridol significantly reduced the expression of endogenous mcl1a compared to vehicle, consist with AML. This new model of MLL-r-AML provides a novel tool to understand the molecular mechanisms underlying disease progression and a platform for drug discovery. Author summary: Acute myeloid leukemia (AML) accounts for over twenty thousand new cases of leukemia per year in the United States. MLL rearrangements (MLL-r) occur in approximately 10% of AML patients, with 34% of those harboring an MLL-ENL or MLL-AF9 rearrangement. Patients with an MLL-r have a higher relapse rate and their overall survival is low, pointing to a need for novel therapeutic interventions. Zebrafish have emerged as a powerful model system to study hematological malignancies due their conserved hematopoietic program, genetic tractability, and pharmacological accessibility. Expression of human MLL-ENL and MLL-AF9 in the myeloid lineage of zebrafish embryos induced an expansion of myeloid cells and caused an increase in expression of endogenous bcl2 and cdk9. MLL expression was significantly reduced in lyz:MLL-ENL and lyz-MLL-AF9 embryos co-treated with the BCL2 inhibitor (Venetoclax) and the CDK9 inhibitor (Flavopiridol) compared to embryos treated with vehicle or either drug alone. Reduced MLL expression occurred in conjunction with a significant decrease in mcl1a expression, consistent with human AML cells. Taken together, these results further support the use of zebrafish to model hematological malignancies for drug discovery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF